For citations:
Shesternya PA, Baranov AA, Vinogradova IB, Anoshenkova ON, Antipova OV, Bogdanova EA, Grabovetskaya YY, Ilivanova EP, Kalyagin AN, Blinova AA, Lapkina NA, Mokrousova MV, Nesmeyanova OB, Nikitina NM, Yudina NV, Alekseev EN, Nasonov EL, Lila AM. Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2024;18(5):54-64. (In Russ.) https://doi.org/10.14412/1996-7012-2024-5-54-64